Evidence map›Paper›PMID 40643516›Full record

ReviewCells2025

Immunotherapy for Platinum-Resistant Ovarian Cancer as a Glimmer of Hope.

Jan Brancewicz, Irena Barbara Padzińska-Pruszyńska, Małgorzata Kubiak, Paulina Kucharzewska

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jan BrancewiczCellis AG, Bleicherweg 45, 8002 Zurich, Switzerland.ORCID 0000-0002-7963-8474
Irena Barbara Padzińska-PruszyńskaCenter of Cellular Immunotherapies, Warsaw University of Life Sciences, Building 23, Level 0, Laboratory Number 0135, 8 Ciszewskiego St., 02-786 Warsaw, Poland.
Małgorzata KubiakCenter of Cellular Immunotherapies, Warsaw University of Life Sciences, Building 23, Level 0, Laboratory Number 0135, 8 Ciszewskiego St., 02-786 Warsaw, Poland.
Paulina KucharzewskaCenter of Cellular Immunotherapies, Warsaw University of Life Sciences, Building 23, Level 0, Laboratory Number 0135, 8 Ciszewskiego St., 02-786 Warsaw, Poland.ORCID 0000-0002-4698-2551

Funding

European Union's Horizon 2022 research and innovation programme No. 101099232Warsaw University of Life Sciences-SGGW and by the MACOV project
6 · The paper itself

Abstract

Ovarian cancer is a leading cause of cancer-related deaths among women, with platinum resistance posing a significant challenge. Conventional therapies often fail in these cases, highlighting the urgent need for novel treatment approaches. Immunotherapy has emerged as a promising strategy, offering renewed hope for patients with platinum-resistant ovarian cancer (PROC). This review explores the current landscape of immunotherapies for PROC, discussing different approaches, their mechanisms of action, and the potential for overcoming the limitations of conventional treatments.

Indexed as

Drug Resistance, NeoplasmImmunotherapyOvarian NeoplasmsPlatinumFemaleHumansPlatinumcancer immunotherapycell-based therapiesovarian cancertumor-associated macrophagestumor microenvironment

Identifiers

PMID40643516
PMCPMC12248509

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.